Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1160/TH09-12-0812 | DOI Listing |
Res Pract Thromb Haemost
February 2023
Department of Medical Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Background: The mixing test is useful to investigate the cause of unexpectedly prolonged activated partial thromboplastin time (APTT). Several indexes are available for distinguishing correction from non-correction (ie, factor deficiency from inhibitors), but their performance characteristics may differ because of their different formulas. Furthermore, it is unclear how each index performs under the coexistence of factor deficiency and inhibitors.
View Article and Find Full Text PDFInt J Lab Hematol
April 2023
Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, Sheffield, UK.
Introduction: Non-parallelism in factor assays can lead to incorrect factor activities. Parallelism can be assessed by calculating the coefficient of variation (CV) of results obtained on 3 dilutions of the same sample. Some authors have proposed that if there is <15% then the average activity is reportable.
View Article and Find Full Text PDFClin Oral Implants Res
September 2019
Department of Periodontology, Oral Implantology, Removable and Implant Prosthodontics, Faculty of Medicine and Health Sciences, Dental School, Ghent University, Ghent, Belgium.
Objectives: This prospective study analyses the 5-year clinical outcome, patient satisfaction and the technical outcome of a 2-implant overdenture on stud abutments. In addition, the influence of mandibular resorption and implant position on these outcomes was assessed.
Material And Methods: Patients received two implants in a one-stage delayed protocol.
Thromb Haemost
November 2014
Jurg M. Sommer, PhD, Biogen Idec, 14 Cambridge Center, Cambridge, MA 02142, USA, Tel: +1 617 914 6937, Fax: +1 888 693 8149, E-mail:
Due to variability in the one-stage clotting assay, the performance of new factor IX (FIX) products should be assessed in this assay. The objective of this field study was to evaluate the accuracy of measuring recombinant FIX Fc fusion protein (rFIXFc) activity in clinical haemostasis laboratories using the one-stage clotting assay. Human haemophilic donor plasma was spiked with rFIXFc or BeneFIX® at 0.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!